The National Health Service (NHS) in the United Kingdom has announced the launch of a groundbreaking immunotherapy vaccine for cancer, which is described as a “major breakthrough” capable of targeting 15 different types of cancer, and can be administered to patients in under five minutes.
The new vaccine, scientifically known as nivolumab, marks a significant change in cancer treatment, expected to revolutionize the way therapy is delivered. Traditionally, it was given through intravenous drip and took an hour to administer, but now it can be provided as a subcutaneous injection in just three to five minutes.
A Significant Advancement in Treatment
It is estimated that approximately 1,200 patients monthly in England could benefit from this new treatment, which covers various types of cancer, including skin, bowel, stomach, kidney, bladder, lung, head and neck, and esophageal cancers, according to the Daily Mail.
Professor Peter Johnson, the national clinical director for cancer at the NHS, stated that this achievement “saves time for both patients and medical staff, making treatment more accessible and flexible,” and added that this initiative “will empower medical teams to treat a larger number of patients.”
Promising Results and Successful Trials
Developed by Bristol Myers Squibb, the vaccine has shown effectiveness during clinical trials, demonstrating comparable results in terms of efficacy and side effects to traditional intravenous treatments. Patients expressed complete satisfaction with the ease of receiving treatment through the quick injection method.
James Richardson, the national cancer drugs adviser, emphasized that “the vaccine represents a significant advancement that can improve the lives of thousands each month, especially those suffering from solid tumors such as kidney and skin cancer.”
Government Support and Recognition of Innovation
Public Health Minister Ashley Dalton, who has previously shared her own experience with breast cancer, welcomed this achievement, stating that “the UK continues to lead in medical innovation, and the new vaccine is a prime example of our ability to transform health challenges into leading therapeutic opportunities.”
She confirmed that patients in England would be among the first in Europe to benefit from this advanced treatment at no additional cost to the NHS, thanks to a commercial agreement with the manufacturer.
Worrying Surge in Cancer Cases
This advancement comes amid growing concerns about the rise in cancer diagnoses, particularly among those under 50, attributed by experts to modern lifestyle factors and chemical exposures.
Recently, the NHS also announced a trial for an innovative blood test utilizing artificial intelligence to detect cancer early by analyzing genetic fragments from tumors in the body, which will be tested on 8,000 patients to identify 12 of the most common cancer types.
A Bright Outlook
The new injection is expected to be implemented in the upcoming weeks as supplies reach the UK, with approximately 40% of patients currently receiving nivolumab treatment via intravenous infusion projected to transition to the faster new version.